Publications

5674 Results

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials [PMID18202421]

Authors
PN Lara Jr;MW Redman;K Kelly;MJ Edelman;SK Williamson;JJ Crowley;DR Gandara
Journal / Conference
Journal of Clinical Oncology 26(3):463-467
Year
2008
Research Committee(s)
Lung
Study Number(s)
S0003, SWOG-9509, S9806

Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer [PMID18172274]

Authors
AL Sabichi;SP Lerner;EN Atkinson;HB Grossman;NP Caraway;CP Dinney;DF Penson;S Matin;A Kamat;LL Pisters;DW Lin;RL Katz;DE Brenner;GP Hemstreet III;M Wargo;A Bleyer;WH Sanders;JL Clifford;HL Parnes;SM Lippman
Journal / Conference
Clinical Cancer Research 14(1):224-229
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9460

Total body irradiation, etoposide, cyclophosphamide and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin's lymphoma: Results of a Phase III randomized trial by the Southwest Oncology Group (SWOG 9438) [PMC2288718; PMID18256325]

Authors
JA Thompson;RI Fisher;M LeBlanc;SJ Forman;OW Press;JM Unger;AP Nademanee;PJ Stiff;SH Petersdorf;A Fefer
Journal / Conference
Blood 111(8):4048-4054
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9438

Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium [PMID18501081]

Authors
TM Beer;B Goldman;CR Nichols;DP Petrylak;M Agarwal;CW Ryan;ED Crawford
Journal / Conference
Clinical Genitourinary Cancer 6(1):36-39
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
S0306

Does the level of prostate cancer risk affect cancer prevention with finasteride?

Authors
IM Thompson;CM Tangen;HL Parnes;SM Lippman;CA Coltman Jr
Journal / Conference
Urology 71(5):854-857
Year
2008
Research Committee(s)
Cancer Control
PMID
PMID18455628
PMC
PMC2692669
Study Number(s)
SWOG-9217

Prostate-specific antigen progression (PSA-P) predicts overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916.

Authors
B Goldman;M Hussain;C Tangen;C Higano;DP Petrylak;NJ Vogelzang;ED Crawford
Journal / Conference
Journal of Clinical Oncology 26(15s):253s, #5015
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346, S9916

S0124: A randomized phase III trial of cisplatin + irinotecan (PI) versus cisplatin + etoposide (PE) in 671 patients (pts) with extensive stage small cell lung cancer (E-SCLC)

Authors
RB Natale;PN Lara;K Chansky;J. Crowley;JR Jett;JE Carleton;JP Kuebler;H Lenz;P Mack;DR Gandara
Journal / Conference
Journal of Clinical Oncology 26(15S):400s, #7512
Year
2008
Research Committee(s)
Lung
Study Number(s)
S0124

SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small cell lung cancer (LSCLC)

Authors
QT Le;J Moon;M Redman;S Williamson;P Lara;Z Goldberg;LE Gaspar;J Crowley;D Moore;DR Gandara
Journal / Conference
Journal of Clinical Oncology 26(15S):402s, #7523
Year
2008
Research Committee(s)
Lung
Study Number(s)
S0222

Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group study 0317.

Authors
C Pan;M Hussey;P Lara;P Mack;R Nagle;J Dutcher;W Samlowski;J Clark;M Gordon;E Crawford
Journal / Conference
Journal of Clinical Oncology 26(15S):262s, #5051
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
S0317

SWOG0345: phase II trial of imatinib in dermatofibro-sarcoma protuberans (DFSP)

Authors
SM Schuetze;CJ Rankin;BP Rubin;JE Butrynski;A Lazar;EC Borden
Journal / Conference
Journal of Clinical Oncology 26(15S):573s, #10580
Year
2008
Research Committee(s)
Sarcoma
Study Number(s)
S0345